SurVaxM Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This SurVaxM Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether SurVaxM can convert its Synthetic peptide vaccine, Therapeutic vaccine profile and survivin biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | SurVaxM (query alias: SurVaxM) |
|---|---|
| Modality / target | Synthetic peptide vaccine, Therapeutic vaccine; survivin; survivin inhibitors |
| Highest global status | Phase 2 |
| Originator | Roswell Park Comprehensive Cancer Center |
| Active developers | Roswell Park Comprehensive Cancer Center, Mimivax LLC, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. |
The MCP disease footprint includes Lung Cancer, Glioblastoma, Glioblastoma Multiforme. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07169617 | Phase 2 | Not yet recruiting | 80 | Primary endpoint not disclosed in English source |
| NCT06202066 | Phase 2 | Suspended | 60 | Primary endpoint not disclosed in English source |
| NCT05163080 | Phase 2 | Unknown status | 247 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Prospective, randomized, placebo-controlled phase 2b trial of SurVaxM plus adjuvant temozolomide in newly diagnosed glioblastoma (SURVIVE).
Phase 2; n=228; evaluation: Positive. Reported fields: OS(1-year) = 75.0 % ; OS(1-year) = 60.0 %
MimiVax Announces Positive Interim Analysis in Ongoing SurVaxM Clinical Trial
Phase 2; n=not disclosed; evaluation: Positive. Reported fields: Efficacy = has successfully progressed following the first interim analysis of trial data.
RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)
Phase 2; n=239; evaluation: Positive. Reported fields: OS = 25.9 Month
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
SurVaxM addresses Lung Cancer, Glioblastoma, Glioblastoma Multiforme. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Synthetic peptide vaccine, Therapeutic vaccine—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2019-11-13 | Shanghai Fosun collaborates with MimiVax to develop and commercialize SurVaxM for glioblastoma in China, including mainland China, Hong Kong, and Macao. | Phase 2 | US$10.0M upfront; US$138.0M milestones; US$148.0M stated total |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “mRNA vaccine and kit and application thereof”. The milestone feed surfaced a patent-application signal described as “Survivin peptides as cancer vaccines”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Immunogenicity durability and clinically meaningful protection
- Population selection, endpoint timing, and comparator relevance
- Manufacturing consistency, distribution, and uptake
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
